Search details
1.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat
; 201(2): 151-159, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37338729
2.
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.
Future Oncol
; 18(19): 2339-2349, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35465733
3.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Eur J Cancer Care (Engl)
; 29(4): e13253, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32578279
4.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Breast Cancer Res Treat
; 174(3): 693-701, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30607629
5.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat
; 177(1): 115-125, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31152327
6.
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Invest New Drugs
; 37(1): 98-108, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29948356
7.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Oncologist
; 22(11): 1301-1308, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28701571
8.
Physical activity and breast cancer risk by pathological subtype.
Gynecol Oncol
; 144(3): 577-585, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28057355
9.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(2): 150-5, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26786263
10.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat
; 156(1): 81-9, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26909792
11.
Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Oncologist
; 20(5): 474-82, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25908555
12.
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Oncologist
; 20(2): 111-2, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25601966
13.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Breast Cancer Res
; 16(2): R38, 2014 Apr 12.
Article
in English
| MEDLINE | ID: mdl-24725534
14.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Breast Cancer Res
; 15(6): R105, 2013 Nov 06.
Article
in English
| MEDLINE | ID: mdl-24192331
15.
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Breast Cancer Res Treat
; 138(2): 457-66, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23423445
16.
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Cancer
; 118(1): 241-7, 2012 Jan 01.
Article
in English
| MEDLINE | ID: mdl-21717449
17.
Bilateral kidney pseudotumor due to sarcoidosis: a radiological study case.
Arch Esp Urol
; 65(6): 629-32, 2012.
Article
in English, Spanish
| MEDLINE | ID: mdl-22832646
18.
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
Clin Cancer Res
; 28(6): 1107-1116, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34980598
19.
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Eur J Cancer
; 168: 12-24, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35429901
20.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(6): 778, 2016 06.
Article
in English
| MEDLINE | ID: mdl-27317735